Nalaganje...
Study partners should be required in preclinical Alzheimer’s disease trials
BACKGROUND: In an effort to intervene earlier in Alzheimer’s disease (AD), clinical trials are testing promising candidate therapies in preclinical disease. Preclinical AD trial participants are cognitively normal, functionally independent, and autonomous decision-makers. Yet, like AD dementia trial...
Shranjeno v:
| izdano v: | Alzheimers Res Ther |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5719524/ https://ncbi.nlm.nih.gov/pubmed/29212555 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-017-0327-x |
| Oznake: |
Označite
Brez oznak, prvi označite!
|